Digestive and Liver Disease - Volume 48 - Supplement 2

e130

Abstracts of the 22

National Congress of Digestive Diseases / Digestive and Liver Disease 48S2 (2016) e67–e231

P.01 Liver 1

P.01.1

A SINGLE INFUSION OF FERRIC CARBOXYMALTOSE EFFECTIVELY

IMPROVES IRON-DEFICIENCY ANEMIA IN PATIENTS WITH

GASTROINTESTINAL AND LIVER DISEASE: A HOSPITAL-BASED

SURVEY

Viola A.*, Cappello M., Cilluffo M.G., Mendolaro M., Craxì A.,

Almasio P.L.

Gastroenterology Section, DiBiMis, University of Palermo, Palermo,

Italy

Background and aim:

Disease of the gastrointestinal (GI) tract

and the liver are common causes of Iron deficiency anemia (IDA).

Traditional therapy with oral iron is often ineffective or is linked

to gastrointestinal side effects. Conventional intravenous (IV) iron

is effective but requires repeated infusions. Ferric carboxymaltose

(FCM) is a novel intravenous iron preparation that can be

administered in single doses. In this retrospective study we aimed

to evaluate efficacy and safety of FCM in a cohort of patients with

IDA related to gastro-intestinal disease.

Material and methods:

We report data of 63 consecutive patients

admitted to our day-care unit because of IDA from January 2014 to

September 2015. Anemia (defined as Hb < 13 g/dl in men, Hb < 12 g/

dl in non-pregnant women) was classified as IDA if ferritin value was

< 30 ng/ml. There were 27 (43%) patients with Inflammatory Bowel

Disease, 17 (27%) with liver cirrhosis, 4 (6%) with celiac disease, 15

(24%) with other G-I disease. Clinical-demographic characteristics

were registered on a dedicated database. We evaluated Hb, serum

iron and ferritin values at baseline, after 2 and 8 weeks. FCM was

administered by intravenous infusion of 500 mg in 15 minutes. We

also evaluated the need for a second infusion of FCM and number

of blood transfusions at baseline and after iron therapy. Safety was

also assessed.

Results:

By a single infusion of FCM, we obtained a mean increase

of 1,3 g/dl in Hb values (Hb levels at baseline 9.5 ± 1.2 g/dl, 10.8 ± 1.5

g/dl at week 2) (p < 0.001). Significant increases in mean levels of

serum iron (31 ± 23 at baseline, 60 ± 33 μg/dL at 2 weeks,

27 µg/

dl; p < 0.001) and ferritin (21.6 ± 47 at baseline, 126 ± 85 ng/mL at 2

weeks,

105 ng/ml; p<0.001) were also observed. A second infusion

of FCM was necessary in 30% of patients. 11 patients (17%) had

required at least one tranfusion before FCM treatment while only 5

patients (8%) needed transfusions after FCM. Only one adverse event

was observed (skin rash). FCM was well tolerated also in 4 patients

with a previous history of anaphylactoid reaction to iv iron.

Conclusions:

A single infusion of FCM significantly improves Hb

and iron status in patients with IDA due to GI disease. Safety profile

was excellent even in patients with liver disease and those with a

previous history of allergic reaction to iron sucrose preparations. The

use of FCM benefits reduces the impact of treatment on everyday

life and work productivity and allowing a more efficient utilization

of hospital resources.

P.01.2

HBV INFECTION PREVALENCE AND VACCINATION IN AN

IMMIGRANT POPULATION IN ROME

Nosotti L.*, Petrelli A., Rossi A., Miglioresi L., Costanzo G., Fortino A.,

D’Arca T., Pecoraro L., Mirisola C.

National Institute for Health, Migration and Poverty (NIHMP), Rome,

Italy

Background and aim:

HBV chronically infects about 400 million

people, in some geographical areas reaching and exceeding an 8%

prevalence. Italy is placed in a HBV low prevalence range (about 1%)

among native population. Still lack of information is observed about

the diffusion of HBV infection in immigrant populations. Aim of the

study is to improve immigrant’s access to screening, diagnosis and

treatment.

Material and methods:

Between March 2013 and June 2014 a

screening for HBV infection was proposed to 516 immigrants coming

from different high and intermediate endemic areas. 449 of them

accepted the blood test.

Vaccination against Hepatitis B was offered to the 209 patients

negative for all markers of HBV infection.

Results:

HBsAg positivity prevalence in patients accessing the

Outpatient Clinic of NIHMP was 7.7%, (41% of them coming from

East Europe, 39% from Africa, 20% from Asia). 67,3% of patients were

males, mean age was 39.5 +/-11.

Among the 449 patients submitted to serological screening, 35 were

positive for HBV infection (HBsAg positive), while 414 patients were

negative for HBV infection (163 patients with immune response

generated by previous infection, 42 with immune response

generated by vaccination and 209 negative for all markers). The

prevalence of HBV infection in the cohort studied is 7.7% (35/449).

Among the 209 patients who received the vaccination against HBV

infection, 68 (32.5%) refused the vaccination, while 141 (67.4%)

began the vaccination cycle.

In addition, the screening showed the low percentage (9.3%) of

patients that had been vaccinated against HBV (42/449), due to a

lack of health education and of vaccination campaigns in their

countries of origin.

Conclusions:

In the cohort of patients studied, HBV infection

prevalence resulted higher than in the general Italian population

(7,7% versus 1%). The reason for this difference can be explained by

considering immigrant’s places of origin, which are often countries

with high endemic HBV infection. We emphasize that, besides

offering the screening test, also the vaccination option was offered

to the immigrants resulting HBV sero-negative; in particular it

is crucial to extend vaccination to cohabiting people and sexual

partners of HBsAg positive subjects.

P.01.3

EFFICACY OF MEDITERRANEAN DIET AND ANTIOXIDANTS IN

OVERWEIGHT PATIENTS WITH NON-ALCOHOLIC FATTY LIVER

DISEASE

Abenavoli L.*

, Milic N.

, Larussa T.

, Suraci E.

, Imeneo M.

Medic M.

, Luzza F.

Department of Health Sciences, University “Magna Græcia”,

Catanzaro, Italy,

Department of Pharmacy, University of Novi Sad,

Novi Sad, Serbia,

Faculty of Medicine, University of Novi Sad, Novi

Sad, Serbia

Background and aim:

Nonalcoholic fatty liver disease (NAFLD)

is the most common liver disease worldwide. The only currently

recommended treatment for NAFLD is lifestyle modification.

However, literature reports many studies on the use of antioxidant

supplementation. The aim of this report is to describe the effects

of Mediterranean diet associated with the administration of

antioxidants (Bilirel – BIL; Pharmaluce, Republic of San Marino) in

overweight patients with NAFLD.

Material and methods:

Forty overweight patients with NAFLD

were consecutively enrolled in this prospective study. The patients

were randomized into two groups (n:20 and n:20). The first group

was treated by Mediterranean diet (1300 kcal/day), and the second

Posters